Pazdur grills PD-1/PD-L1 companies over lack of collaboration, trial redundancies

FDA's Oncology Center of Excellence Director Richard Pazdur pressed representatives from companies with marketed PD-1/PD-L1 inhibitors to explain why they aren't collaborating more in the clinic while questioning whether there are too many of these drugs on the market. His comments came as he moderated a session at the American Association for Cancer Research (AACR) meeting on Monday titled "PD-1 Pandemonium."

Pazdur chastised companies for failing to work together to develop biomarkers and conduct

Read the full 733 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE